UW Home > Medicine > Allergy and Infectious Disease > UWVRC


 

Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2

 

Men and Women
Drug study
Swabbing study
Blood draws

Purpose: The purpose of this study is to study the effectiveness of the standard, FDA-approved dose of acyclovir (400 mg twice daily) compared to no medication in reducing rapidly cleared episodes of herpes virus shedding in persons that are infected with HSV-2.

Study Visits and Procedures: Involvement in the study will last 9-weeks and participants will be asked to visit the clinic every 2-weeks. This study is what is known as a randomized, cross-over study. This means we will make comparisons between two study groups. Randomization means that participants are put into a group by chance, like flipping a coin. One study group will begin by receiving acyclovir and the other study group will begin by taking no medication. “Crossover study” means that after 4-weeks, participants will go to the other study arm. Participants will asked to complete a daily symptom diary and collect daily home swabs 4-times a day, everyday during the study.

We need:
We provide:
  • Men and women age 18 or older
  • HIV seronegative
  • HIV seropositive, CD4 count >250 and not taking antiretroviral therapy
  • Women cannot be pregnant or planning to become pregnant, and must use birth control throughout duration of study
  • HSV, HIV, and pregnancy testing
  • $210 for completion of the entire study
 
 
 
[University of Washington]

vrc@u.washington.edu
Modified: August 6, 2008